Short answer
Bruker Corp (BRKR) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Effective July 1, 2026, Bruker reorganized reportable segments from four legacy structures into four new operating segments.
Bruker Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Effective July 1, 2026, Bruker reorganized reportable segments from four legacy structures into four new operating segments
- BSI BIOS expanded to include BioSpin, SciY, CST, Daltonics, Optics and Mimetas
- BMID created for Microbiology, Molecular Diagnostics and Biomedical Systems, formerly within BSI CALID
- Reorganization does not change historical consolidated results, financial position or cash flows
- Exhibit 99.1 provides recast segment information for investor comparison across 2024-2026 periods
Item EX-99.1 · Exhibit EX-99.1
- Segment recast separates BioSpin into BIOS and BMID, improving comparability of operating performance
- Six-month 2026 revenue $1,661.9M, up from $1,598.8M in 2025
- Six-month 2026 operating loss $55.1M versus $43.7M income, driven by BSI NANO loss $42.7M and Corporate costs $67.8M
- Recast BIOS generated $757.6M revenue and $58.8M operating income in six months
- 2025 full-year recast BIOS contributed $1,580.1M revenue and $168.8M operating income, while BMID contributed $508.9M and $88.8M respectively
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Bruker Corp 8-K filings
Get the next BRKR 8-K as it lands
Follow BRKR for push alerts, or ask the research agent what this filing means.